USE OF ERIBULIN AND S-1(OR 5-FU) AS COMBINATION THERAPY FOR CANCER TREATMENT

摘要

PROBLEM TO BE SOLVED: To provide a method for: (i) reducing the number of cancer cells of cancer that consists of breast cancer, lung cancer, ovarian cancer, endometrial cancer, stomach cancer, rectal cancer, head and neck cancer, and pancreatic cancer; (ii) reducing a tumor volume; (iii) increasing a tumor reduction rate; (iv) reducing or delaying cancer cell infiltration to peripheral organs; (v) reducing or delaying tumor metastasis; (vi) reducing or preventing tumor proliferation; (vii) preventing or delaying occurrence of cancer and/or recurrence of cancer, and/or extending a disease-free survival time or a tumor-free survival period; (viii) increasing an overall survival period; (ix) reducing frequency of treatment; and/or (x) alleviating one or more symptom related to cancer.SOLUTION: Eribulin (e.g., eribulin mesylate) is administrated in combination with S-1 or 5-FU.